Yüksel Ürün: Mirvetuximab Soravtansine (MIRV) shows promise in platinum-resistant ovarian cancer

Yüksel Ürün, Medical Oncologist at Ankara University, shared on X/Twitter:

”Mirvetuximab Soravtansine (MIRV) shows promise in platinum-resistant ovarian cancer! In a recent trial, MIRV led to better survival rates and fewer serious adverse events compared to standard chemo. Personalized treatment could be the future!”

For the article click here.
Source: Yüksel Ürün/X